<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BIO International Convention</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Makary lays out FDA’s path, launches pilot review program</title>
      <description>
        <![CDATA[On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the agency unveiled a pilot commissioner’s national priority voucher program that will enable companies to receive a shortened FDA review time of one to two months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721507</guid>
      <pubDate>Fri, 20 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721507-makary-lays-out-fdas-path-launches-pilot-review-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/BIO-Crowley-and-Makary-618.webp?t=1750277408" type="image/jpeg" medium="image" fileSize="717405">
        <media:title type="plain">BIO2025: John Crowley and Martin Makary</media:title>
        <media:description type="plain">FDA Commissioner Martin Makary, right, talks with BIO CEO John Crowley on Tuesday during a fireside chat at BIO's International Convention in Boston. Source: Biotechnology Innovation Organization</media:description>
      </media:content>
    </item>
    <item>
      <title>BIO 2025: Makary lays out FDA’s path, launches pilot review program</title>
      <description>
        <![CDATA[On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the agency unveiled a pilot commissioner’s national priority voucher program that will enable companies to receive a shortened FDA review time of one to two months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721335</guid>
      <pubDate>Wed, 18 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721335-bio-2025-makary-lays-out-fdas-path-launches-pilot-review-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/BIO-Crowley-and-Makary-618.webp?t=1750277408" type="image/jpeg" medium="image" fileSize="717405">
        <media:title type="plain">BIO2025: John Crowley and Martin Makary</media:title>
        <media:description type="plain">FDA Commissioner Martin Makary, right, talks with BIO CEO John Crowley on Tuesday during a fireside chat at BIO's International Convention in Boston. Source: Biotechnology Innovation Organization</media:description>
      </media:content>
    </item>
    <item>
      <title>BIO 2025: Bridging the gap with a ‘molecule-to-medicine expressway’</title>
      <description>
        <![CDATA[For years, the biopharma industry has spent increasing amounts of money on R&D without improving success rates, leaving many executives searching for new, more predictable drug development paths.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721326</guid>
      <pubDate>Tue, 17 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721326-bio-2025-bridging-the-gap-with-a-molecule-to-medicine-expressway</link>
    </item>
    <item>
      <title>BIO 2025: Building biosecurity through public-private partnership</title>
      <description>
        <![CDATA[The COVID-19 pandemic sent the world into a tailspin, raising ongoing concerns about biosecurity, a subject that encompassed the better part of the morning June 16, the first day of the Biotechnology Innovation Organization’s annual conference in Boston.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721312</guid>
      <pubDate>Mon, 16 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721312-bio-2025-building-biosecurity-through-public-private-partnership</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/DNA-strand-over-digital-lock-and-circuit-background.webp?t=1750110558" type="image/jpeg" medium="image" fileSize="519365">
        <media:title type="plain">DNA strand over digital lock and circuit background</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO 2022: Global trials face core challenges from privacy laws</title>
      <description>
        <![CDATA[As a growing roster of nations moves to protect individual genomic and other health data in the name of privacy under the General Data Protection Regulation in the EU and similar laws elsewhere, chief aggregators of such data, drug developers, are struggling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520185</guid>
      <pubDate>Tue, 28 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520185-bio-2022-global-trials-face-core-challenges-from-privacy-laws</link>
    </item>
    <item>
      <title>BIO 2022: Global trials face core challenges from privacy laws</title>
      <description>
        <![CDATA[As a growing roster of nations moves to protect individual genomic and other health data in the name of privacy under the General Data Protection Regulation in the EU and similar laws elsewhere, chief aggregators of such data, drug developers, are struggling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/520128</guid>
      <pubDate>Mon, 27 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/520128-bio-2022-global-trials-face-core-challenges-from-privacy-laws</link>
    </item>
    <item>
      <title>BIO 2022: Push to model disease biology advancing, but slowly</title>
      <description>
        <![CDATA[With just 10% of therapeutic programs successfully moving from first toxicity dose to market, drug developers are on a constant hunt for new tricks to put the odds in their favor. Strategies abound, from biomarker-guided patient selection to deeper regulatory engagement. But big pharma executives and an academic expert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in-silico modeling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519968</guid>
      <pubDate>Tue, 21 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519968-bio-2022-push-to-model-disease-biology-advancing-but-slowly</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-tech-head.webp?t=1588275796" type="image/png" medium="image" fileSize="375191">
        <media:title type="plain">Head filled with digital data</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO 2022: Despite record number, life sciences talent still hard to come by</title>
      <description>
        <![CDATA[Amid a convergence of demographic, economic and technological trends, more workers are engaged in U.S. life sciences research than ever before, a new analysis of U.S. Bureau of Labor Statistics shows. The analysis, by commercial real estate giant CBRE Group Inc., found that even with a doubling in the number of U.S. graduates in biological and biomedical sciences since 2005, biopharma companies continue to face major challenges finding talent and, increasingly, space in which to put that talent to work.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519880</guid>
      <pubDate>Fri, 17 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519880-bio-2022-despite-record-number-life-sciences-talent-still-hard-to-come-by</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Life-sciences.webp?t=1683033198" type="image/jpeg" medium="image" fileSize="291424">
        <media:title type="plain">Lab glassware and scientist</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO 2022: Push to model disease biology advancing, but slowly</title>
      <description>
        <![CDATA[With just 10% of therapeutic programs successfully moving from first toxicity dose to market, drug developers are on a constant hunt for new tricks to put the odds in their favor. Strategies abound, from biomarker-guided patient selection to deeper regulatory engagement. But big pharma executives and an academic expert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in-silico modeling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/519801</guid>
      <pubDate>Wed, 15 Jun 2022 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519801-bio-2022-push-to-model-disease-biology-advancing-but-slowly</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-tech-head.webp?t=1588275796" type="image/png" medium="image" fileSize="375191">
        <media:title type="plain">Head filled with digital data</media:title>
      </media:content>
    </item>
  </channel>
</rss>
